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1  |  INTRODUC TION
Chronic hepatitis C virus (HCV) is one of the world’s leading causes 
of liver cirrhosis and hepatocellular carcinoma with wider health 
impacts like cardiovascular disease, mental health issues and renal 
complications.1,2 HCV is a blood- borne virus that impacts around 71 
million people globally and approximately 34,500 people in Scotland 
where it is transmitted most commonly through injection drug use.1,2
While there is some emerging evidence that antibodies may be 
partially protective,3 there is no vaccine available, making prevention 
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Abstract
Chronic hepatitis C virus (HCV) is one of the leading causes of liver cirrhosis and hepa-
tocellular carcinoma. The WHO 2030 Elimination Goals require each country to evalu-
ate their response to their epidemics. This can be achieved by visualization of cascades 
of care, depicting how infected cases move through disease control stages. However, 
methods of displaying data are debated and lack practical application. This project pro-
poses a new way of codifying and displaying HCV data using Tayside as a case study. 
1464 cases of active HCV infections in Tayside from 2015 to 2019 were analysed from 
NHS Tayside’s HCV Database. Variables were evaluated to create a systematic coding 
framework that was then used to code each patient’s diagnosis, treatment and cure 
status each year from 2015 to 2019. Graphical representation of the data in the form 
of a stacked clustered bar chart demonstrates general trends and conversion rates. 
For example, Tayside has seen an increase in diagnosis- to- cure rates from 18% to 49% 
(2015- 2019). This method also demonstrates the portion of newly and previously diag-
nosed people accessing treatment, those with unsuccessful or incomplete treatments, 
completed treatments with unconfirmed cure, and the number of deaths and reloca-
tions. In conclusion, this project proposes a novel way of displaying cascades of care 
data that relays yearly snapshots of an epidemic, cumulative progression over time, 
nuanced information of each stage and progression towards elimination targets. This 
method can be meaningfully used to improve local service planning, knowledge ex-
change across health systems and reporting to bodies like the WHO.
K E Y W O R D S
communicable diseases, epidemiology, hepatitis, hepatitis C, public health
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
2  |    BAIANO et Al.
difficult and reinfections common in high- risk populations. The variable 
diagnosis- to- cure journeys, transient populations and possibility of rein-
fection present challenges to health services attempting to monitor and 
visualize the progression of their epidemic or the efficacy of pathways.
HCV was once treated with interferon- based regimens, which were 
lengthy and posed significant side effects, mediocre cure rates and poor 
compliance.2 Between 2013 and 2015, direct acting antivirals (DAAs) 
became the standard of care for many countries like Scotland, providing 
an easily administered oral option with over 95% efficacy across geno-
types.4 With the introduction of DAAs, eradication of the disease has 
become possible and the World Health Organization (WHO) has set 
Elimination Goals for 2030 tasking each health system with evaluating 
their own epidemic and progress towards said targets. These include a 
90% diagnosis rate, 80% treatment rate of those eligible, 90% reduction 
in incidence and 65% reduction in mortality.5 The WHO has highlighted 
priority actions for countries such as information gathering, prevention, 
national target setting and revising plans as necessary.6
In order to monitor both the progression of an epidemic towards 
targets and utilize the metrics to make strategic healthcare provision 
decisions on the ground, data must be collected and communicated 
effectively. Insights about an infectious disease epidemic, like that of 
HCV, can be gained by analysing a health system’s cascade of care 
(CoC) which depicts how infected cases move through the steps of 
effective disease control in a continuum of services.7 CoC has been 
effectively used to identify gaps in HCV care, plan service delivery to 
intensify efforts in key areas, evaluate the progression of the epidemic 
and monitor health system effectiveness in order to improve the 
health and increase the treatment rates of those living with HCV.8- 11
While CoC is used around the globe, approaches to data coding, anal-
ysis and reporting vary.12 Hepatitis C specialist teams have debated the 
best ways to capture yearly snapshots of the current state of the epidemic, 
appreciate how the epidemic changes over time, emphasize the nuances 
at each stage of the cascade and compare how progress meets set targets. 
A standardized method would facilitate the comparison and knowledge 
exchange across time, settings, subpopulations and health systems.6
In order to evaluate yearly snapshots of an epidemic, its cu-
mulative evolution over time, nuance at each stage of the cascade 
and progression towards elimination targets, this paper proposes a 
novel, systematic way of codifying HCV cases along the proposed 
cascade of Care: Diagnosis, Treatment and Cure. It also evaluates 
the hepatitis C cascade of Care in Tayside, Scotland, to provide ex-
amples of insights gained from displaying data in this way.
2  |  METHODOLOGY
2.1  |  Data sources
NHS Tayside maintains records of all patients who have tested posi-
tive for hepatitis C RNA or antibodies since 1993, including those 
who are only temporarily in the region, those who spontaneously 
resolve the infection and have undetectable HCV RNA levels and 
those who have relocated from the region either temporarily or in-
definitely. The current database holds demographic and clinical in-
formation of 3917 people over 18 years old.
In order to capture each patient’s HCV timeline, variables includ-
ing PCR positive test dates, past medical history, DAA treatment 
start dates and statuses, cure dates, death dates and relocation his-
tory were collated from the local HCV database, NHS Tayside Clinical 
portal and Sunquest Integrated Clinical Environment (ICE) system, 
which reports patients’ laboratory results. Qualitative information 
regarding treatment status and relocation history was gathered from 
clinical letters recorded from the pharmacy service, harm- reduction 
service, Tayside Substance Misuse Service, and other health or social 
care services, where available. Caldicott Guardian approval was ob-
tained to access patient data (ref: IGTCAL4762).
2.2  |  Cohort selection
A cohort of individuals with active infections after the widespread 
introduction of DAAs in 2015 was identified. The inclusion and ex-
clusion criteria are outlined in Table 1. For clarity, those that began 
treatment with DAAs in late 2014 and finished in 2015 were in-
cluded as they were the early adopters of what would become 
standard care in 2015 (n = 9). Also, those treated with interferon 
after 2015 were included as they were part of a clinical trial and con-
tributed to Tayside’s overall epidemic (n = 70); any subsequent infec-
tions and treatments with DAAs in these individuals were coded 
as usual. All HCV positive people that were prisoners for at least 
two months in Her Majesty’s Prison (HMP) in Perth were included 
as they fall under Tayside’s medical service provision, contribute to 
Tayside’s prevalence and potentially transmit to other Tayside resi-
dents for the duration of their stay. Those that moved in and out of 
Tayside more than two times over the five years were not consid-
ered residents in Tayside and were, therefore, excluded from the 
TA B L E  1  inclusion and exclusion criteria
Inclusion Criteria: Exclusion Criteria:
a. Any patient alive at any point from 1st January 2015 – 31st December 
2019 AND
b. In Tayside for longer than 2 months (including those in custody of Tayside 
HMP) AND
c. With at least one HCV infection (PCR positive, DBST positive or antibody 
positive with no subsequent negative PCR)
a. Any patient treated and cured prior to 1st January 2015
b. Any patient that died before 2015
c. Any patient that spontaneous resolved before 2015 
(Antibody positive, PCR Negative)
d. Any patient in Tayside for less than 2 months
e. Tayside residents who moved away from Tayside before 
2015 and did not return
f. Tayside residents still in custody of HMP outside of Tayside
Any patient diagnosed and treated before 2015 without a successful SVR, 
that was alive in Tayside between 2015 and 2019
Any patient in Tayside treated with DAAs starting in 2014 and ending in 2015
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analysis. All people that had been treated before 2015 and had not 
had confirmed SVRs and people with a positive antibody test but 
no subsequent PCR data have been included as they may still have 
active infections. Reinfections in the same person, whether in the 
same year or in subsequent years, are coded as separate infections, 
treatments and cures.
Figure 1 outlines the cohort selection process based on inclu-
sion/exclusion criteria. 1476 people that were alive, in Tayside, and 
had at least one active hepatitis C infection since 2015 were ulti-
mately included in the study cohort.
2.3  |  Coding framework
Using the variables to identify important statuses in the diagnosis- 
to- cure journey, a framework was created to codify each patient’s 
Diagnosis, Treatment and Cure status at each point in time (Table 2). 
The coding framework was then used to codify each of the 1476 
patients in our data set each year from 2015 to 2019 to produce an 
example stacked clustered bar chart. Details of the methodological 
nuances and special considerations that are important in replicating 
this method are detailed in Table 3.
3  |  RESULTS
The coding framework was used on the Tayside data set to produce 
an example stacked clustered bar chart (Figure ) with the supporting 
raw data (Figure 2B).
Similarly to previous methods used, this method of displaying 
a cascade of care communicates the basic disease control stages: 
Diagnosis, Treatment and Cure. It provides a cumulative overview of 
the epidemic’s progression during a period of time while also allow-
ing for yearly comparison of the disease control stages.
Conversion rates, which indicate the percentage of people per 
year who move from diagnosis to treatment or cure, help to note 
overall progression towards defined targets and identify specific 
periods of success or struggle in the elimination efforts. In Tayside, 
diagnosis- to- treatment rates went from 19% (2015) to 50% (2019) 
and diagnosis- to- cure rates went from 18% (2015) to 49% (2019). 
Both diagnosis- to- treatment and diagnosis- to- cure rates saw the 
most significant rise from 2016 to 2017.
The method also provides a variety of nuance and distinction 
within each stage by offering 12 sub- stages of the cascade instead 
of the usual 3 (Diagnosis, Treatment and Cure). All of the following 
numerical figures for Tayside are expressed as averages from 2015 
to 2019 unless otherwise specified.
Firstly, those who are unsuitable for treatment for clinical rea-
sons will not progress through the cascade and are important to 
distinguish. Patients unsuitable for treatment include those that are 
palliating with advanced disease from other organs or those in which 
DAAs are contraindicated. In Tayside, 2% of diagnosed patients fall 
in this category.
Secondly, previously diagnosed patients and newly diagnosed 
patients are stratified both at the Diagnosis and Treatment stages. 
This is useful in clarifying the portion of patients with new diagno-
ses each year and to identify barriers in progressing new or previ-
ously diagnosed patients from Diagnosis to Treatment. In Tayside, 
the number of newly diagnosed patients is broadly similar year- on- 
year while the number of previously diagnosed patients decreases. 
Each year, 34% of newly diagnosed patients and 29% of previously 
diagnosed patients enter treatment. Newly diagnosed patients pro-
gressing to treatment increased from 12% (2015) to 60% (2019), and 
previously diagnosed patients progressing to treatment increased 
from 19% (2015) to 36% (2019).
Thirdly, unsuccessful and incomplete treatments are evidenced 
to clarify whether efforts need to be put into improving treatment 
types or increasing treatment compliance, respectively. In Tayside, 
3% of treatment courses are unsuccessful and 6% of courses are 
incomplete. It is interesting to note that 23 people who did not 
complete treatment still achieved SVR. Of these, 1 patient partially 
completed a 24- week course of interferon [8 weeks], 8 partially 
completed an 8- week course of DAAs (Range = 2- 7 weeks, Median = 
4.5 weeks), 13 partially completed a 12- week course of DAAs (Range 
= 1- 11 weeks, Median = 6 weeks), and 1 was unclear.
Fourthly, the portion of patients who have completed treatment 
but do not have a confirmed SVR is shown to provide information on 
patients that require follow- up. In Tayside, the service is still attempt-
ing to follow- up 5% of patients to confirm their post- treatment SVR 
status.
Lastly, deaths and patients that relocate are shown at each stage of 
the cascade. In Tayside, 4% of patients died and 2% moved each year.F I G U R E  1  Cohort selection based on inclusion/exclusion criteria
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4  |  DISCUSSION
The coding framework suggested in this paper could be applied 
across healthcare systems to add nuance to stages of the cascade 
and to standardize definitions. This could facilitate the comparison 
across settings and systems, providing a potential reporting method 
the WHO might suggest to countries tracking their epidemics. An 
example of how the framework can be practically applied to any sys-
tem’s HCV data can be found in Appendix 1.
The proposed stacked clustered bar chart displays the cascade 
of care data in a way that relays yearly comparisons of an epidemic, 
cumulative progression over time, nuance between disease control 
stages and relation to elimination targets. It provides insights into 
how well people are moving through the cascade towards Cure, what 
initiatives are successful, and where challenges may be. This has key 
implications for health care planners and commissioners that want 
a deeper understanding of what is fuelling or hindering the local 
epidemic.
TA B L E  2  Coding framework
Category Code Definition
Diagnosis Previous Diagnosis Patients with an active HCV infection, first diagnosed before 
the given year that has not been treated successfully or 
spontaneously resolved
New Diagnosis Patients with an active HCV infection, first diagnosed at any point 
in the given year
Can’t Treat Patients with an active HCV infection first diagnosed at any point 
in the given year that are unsuitable for treatment, usually for 
palliative reasons
Moved Patients with an active HCV infection first diagnosed at any 
point in the given year or beforehand that has moved before 
progressing to treatment
Dead Patients with an active HCV infection first diagnosed at any 
point in the given year or beforehand that has died before 
progressing to treatment
Treatment Treatment - Previous Diagnosis Treatment of a patient with an active HCV infection, first 
diagnosed before the given year that has not been treated 
successfully or spontaneously resolved
Treatment - New Diagnosis Treatment of a patient with an active HCV infection, first 
diagnosed at any point in the given year
Treatment Unsuccessful Unsuccessful treatment of a patient with an active HCV infection 
first diagnosed at any point in the given year or beforehand
Treatment Incomplete Incomplete treatment of a patient with an active HCV infection 
first diagnosed at any point in the given year or beforehand
Moved Patients with an active HCV infection treated at any point in the 
given year that has moved before progressing to cure
Dead Patients with an active HCV infection treated at any point in the 
given year that has died before progressing to cure
Cure Cure Patients who have achieved a clear Sustained Virologic Response 
(SVR), defined by HCV RNA below the lower level of 
detection, 12 weeks post- treatment; assigned to the year the 
treatment started
Spontaneously Resolved Patients who have a negative PCR test after previously having a 
positive PCR test but have not accessed treatment; assigned 
to the year of the negative test.
Unknown SVR Patients who have completed treatment, but their SVR status 
has not been confirmed; assigned to the year the treatment 
started
Moved Patients who have moved after completing treatment but before 
confirming they have achieved SVR; assigned to the year the 
treatment started
Dead Patients who have died after completing treatment but before 
confirming they have achieved SVR; assigned to the year the 
treatment started
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Having used the method to analyse the Tayside data, it was evi-
dent that the area has been successful at both managing and track-
ing the local HCV epidemic. This may be attributed to their quick 
transition from interferon- based treatments to DAAs in 2015 and 
universal access to treatment provided for virtually all those in-
fected. Tayside has utilized innovative testing and treatment path-
ways, some of which are located within community pharmacies and 
harm- reduction centres, to widen access to services at each stage 
of the cascade.13- 15 As in many settings, there are continuing chal-
lenges in providing services to those that are hardest to reach, such 
as those that frequently relocate or those that may not regularly en-
gage with healthcare services.
Beyond Tayside, the method proposed in this paper can be im-
plemented with basic spreadsheet tools that have pivot table and 
graphing functions. While the method, as described here, has been 
created to meet Tayside’s needs using their rich data collection and 
Diagnosis Reinfections, whether in the same year or in subsequent years, are coded 
separately as individual infections.
Patients with a positive DBST and negative PCR taken on the same day are 
considered negative as PCR is a more specific test.
The small number of patients that are diagnosed in Tayside, move away and 
return to Tayside at a later date with an active infection are first coded as 
“New Diagnosis” and upon return coded as “Diagnosis Carrier.”
Treatment Though rare, multiple treatments for the same infection, whether in the same 
year or in subsequent years, are coded separately as individual treatments.
Patients coded as “Treatment Unsuccessful” or “Treatment Incomplete” without 
a confirmed SVR for one year are coded as “Previous Diagnosis” for the 
successive year as they had not cleared the virus and are still pending a 
successful treatment.
Though it is difficult to distinguish between a spontaneous resolution + 
reinfection or if the treatment was unsuccessful without genotyping each 
sample, patients who have a continually high viral load who have completed 
treatment without an SVR are coded as “Treatment Unsuccessful.” Some 
samples are genotyped and if there is a distinct change in genotype, the 
cases are coded as two separate infections.
Diagnosis- to- treatment rates are calculated by all patients in a specific year 
that are at the treatment stage (“[Treatment] – [Previous Diagnosis]” + 
“[Treatment] – [New Diagnosis]” + “[Treatment Unsuccessful]” + “[Treatment 
Incomplete]” + “[Treatment] – [Moved]” + “[Treatment] – [Dead]”) divided by 
“[Previous Diagnosis]” + “[New Diagnosis]” for that same year.
New Diagnosis Treatment and Previous Diagnosis Treatment rates are calculated 
by dividing “[Treatment] – [New Diagnosis]” by “[New Diagnosis]” and 
“[Treatment] – [Previous Diagnosis]” by “[Previous Diagnosis]”, respectively.
Unsuccessful and Incomplete Treatment proportions are calculated by dividing 
“[Treatment Unsuccessful]” or “[Treatment Incomplete]” by “[Treatment] 
– [Previous Diagnosis]” + “[Treatment] – [New Diagnosis]” + “[Treatment 
Unsuccessful]” + “[Treatment Incomplete].”
Cure Cured cases are coded in the year that they started treatment.
Since very high real world SVR rates have been observed in patients who 
completed treatment, patients with an End of Treatment Negative result are 
coded as achieving “Cure.”
Patients who have completed treatment but have not returned for SVR bloods 
are coded as “Unknown SVR” each year until they either have SVR bloods 
or a new PCR positive test, at which point they will again be coded as 
“Diagnosis.”
Patients that do not complete treatment but achieve SVR are coded as 
“Treatment Incomplete” and “Cure”
Patients coded as “Dead” at the cured stage have completed treatment and are 
awaiting SVR bloods when they pass.
Diagnosis- to- cure rates are calculated by “[Cure]” + “[Unknown SVR]” + “[Cure] 
– [Moved]” + “[Cure] – [Dead]” from a specific year divided by “[Previous 
Diagnosis]” + “[New Diagnosis]” for that same year.
Unknown SVR rates are calculated by “[Unknown SVR]” divided by “[Cure]” + 
“[Unknown SVR].”
General Deceased patients are coded as “Dead” within the last stage of the cascade that 
they completed in the year that they passed.
Patients that move away from the region are coded as “Moved” within the last 
stage of the cascade that they moved.
TA B L E  3  Methodological nuances and 
special considerations
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storage processes, the method is malleable and could be adapted to 
other settings. Areas with less robust data can combine or remove 
codes to produce a more simplified version of the CoC, though this 
may impact the nuance and utility of the information. Similarly, new 
codes, such as reinfections, could be developed if useful to that local 
setting. Adding codes provides more helpful detail; however, it also 
increases the burden of data collection, adds complexity to the chart 
and loses the standardization of definitions. Further research is war-
ranted to understand how this method might be applied in various 
healthcare settings with different diagnosis pathways, treatment 
services and levels of data keeping.
In conclusion, overall, this project proposes a novel way of 
codifying and displaying cascades of care data that relays yearly 
comparisons of an epidemic, overall progression over time, nuance 
within disease control stages and progress towards elimination tar-
gets. The coding framework can be used to standardize definitions 
across settings and the stacked clustered bar chart improves ser-
vice evaluation to offer insights to healthcare planners who want 
a comprehensive understanding of what fuels or hinders a local 
cascade. More broadly, it can facilitate knowledge exchange across 
global health systems and offer a new way to track global infec-
tious epidemics.
F I G U R E  2  A, 2015- 2019 Tayside cascade of care. B, 2015- 2019 Tayside raw data
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